Eribulin Glenmark Pharmaceuticals Europe

Eribulin is a medication used for specific cancer treatments. This intravenous drug is manufactured by Glenmark Pharmaceuticals Europe Limited and is designed for targeted therapy.

Eribulin is primarily used in the treatment of certain types of cancer. It is often prescribed for metastatic breast cancer and other advanced cancers. The drug works by targeting cancer cells to slow their growth and spread. Patients and healthcare providers often discuss what Eribulin is used for in the context of advanced cancer treatments.

Common effects of Eribulin may include fatigue, nausea, and hair loss. Some patients may experience peripheral neuropathy, which can cause numbness or tingling in the hands and feet. These effects can vary in intensity and duration among individuals.

Eribulin should be handled with care and administered by healthcare professionals. It is important to follow the prescribed dosage and monitor for any adverse reactions. Patients should inform their healthcare provider about any existing medical conditions or medications they are taking.

Eribulin may interact with other medications, including those that affect liver enzymes. It is advisable to avoid alcohol while undergoing treatment with Eribulin. Patients should consult their healthcare provider for specific interaction concerns.